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A B ST R AC T 
 
 
The screening for pre-invasive cervical lesions has significantly decreased 
the incidence of cervical neoplasm. It is recommended to be performed 
starting with the age of 21 with a frequency of 3-5 years and it consists of 
pap smear testing and HPV genotyping, and, if required, it can be continued 
with colposcopy or biopsy followed by pathological assessment. The 
importance of the early diagnosis of pre-invasive cervical lesions has led to 
several studies on this topic. The paper analyzed the modern literature 
published on the PubMed and Scopus databases. Reference studies have 
found that most intraepithelial lesions are caused by the presence of HPV. 
Other commonly associated factors are immunosuppression, multiparity and 
other viral infections. HPV infection can be prevented by vaccination. It is 
recommended for people between 11 and 26 years old and also over 27 years 
old if they associate risk factors. A meta-analysis performed on patients 
diagnosed with CIN2 revealed a lower recurrence rate in vaccinated women 
than in unvaccinated women. Other studies have shown the transient nature 
of HPV infection and spontaneous regression of pre-invasive lesions. The 
early diagnosis of pre-invasive lesions is necessary for the initiation of 
therapeutic and follow-up behavior as soon as possible, with the aim of 
reducing the incidence of cervical cancer. This is possible and easy to access 
through national health programs.   
 
Category:  Review 
Received:  March 16, 2021 
Accepted:  May 14, 2021 
Published:  October 10, 2021 
Keywords:  
HPV, Papanicolau test, cervix neoplasm, diagnostic 
algorithm 
*
Corresponding author:  
Oana Denisa Balalau, 
Carol Davila University of Medicine and Pharmacy, 
Department of Obstetrics and Gynecology, Dionisie Lupu St. 
No. 37, Bucharest, Romania, 020021 




The early diagnosis of pre-invasive cervical lesions has 
been a challenge since the twentieth century. National 
screening programs have been developed to reduce the 
incidence of cervical cancer, but this pathology remains a 
public health problem. In the United States, the incidence 
of malignant tumor pathology of the cervix has decreased 
since the 1970s, after the evolution of the first national 
screening programs [1,2]. 
Intraepithelial cervical lesions (CIN) are premalignant 
lesions of non-keratinized multilayered epithelial covering 
tissue [3]. The cervix consists of endocervix (cylindrical 
epithelium) and exocervix (squamous epithelium). The 
screening for pre-invasive and invasive cervical lesions 
includes Pap smear and HPV genotyping. Depending on the 
results, these investigations can be completed with 
colposcopic examination and pathological assessment [4,5]. 
In order to be able to diagnose these lesions at an early 
stage, every woman older than 21 years old has to undergo 
screening tests: Papanicolau smear (Pap smear) once every 
three years, or HPV genotyping together with Pap smear 
every 5 years [6,7]. 
Pap smear examines cervical cellularity, thus being able 
to diagnose malignant intraepithelial lesions, inflammation, 
atrophy, or other physiological and pathological changes in 
the cervical epithelium [8,9]. On the referral note of the 
cytological examination, one must specify the date of the last 
menstruation, the presence of intrauterine devices and 
pregnancy [10]. HPV genotyping seeks to multiply the HPV 
genome to identify viral strains [11]. 
For the diagnosis of intraepithelial cervical lesions, the 
colposcopic examination is also used, which analyzes the 
modifications of the external layer of the cervix and of the 
squamous-columnar junction. The investigation is 
indicated in case of unfavorable results at Pap smear 
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examination or HPV genotyping [12]. During the 
colposcopic examination, a tissue fragment can be 
collected for the histopathological examination. This 
procedure does not require the hospitalization of the  
patient and it has few contraindications: cervicitis, 
hemorrhagic diathesis, vaginal bleeding, pregnancy and 
immunosuppression [13,14]. 
The next step in the diagnosis of the lesions is the 
pathological evaluation. Conization together with the 
diathermic loop electro resection and bioptome biopsy are 
reliable methods that provide tissue for the 
histopathological examination. Uterine curettage is not a 
routine indication if conization is performed. It is indicated 
only if there are glandular cell abnormalities on Pap smear 
or if they have risk factors for endometrial hyperplasia or 
endometrial adenocarcinoma [15]. 
The literature search was conducted in PubMed and 
Scopus databases using the terms “Cervical intraepithelial 
lesions”, “excisional procedures” and “screening and 
diagnostic for cervical lesions”. No date restriction was 
applied. Language was restricted to English and French. 
Additional studies from the reference list of the articles 
were searched. 
Discussions 
CIN occurs most frequently in the squamous-columnar 
junction, being secondary to the HPV infection. Most 
intraepithelial lesions are thought to be caused by HPV, but 
not all HPV infections cause CIN [16,17]. Besides the HPV 
infection, other risk factors are immunosuppression, diet, 
multiparity, first delivery before the age of 17 years, 
multiple sexual partners, lack of condom use, smoking, 
herpes virus infection. A study conducted by Anttila 
revealed that Chlamydia trachomatis has an implication in 
the development of pre-invasive lesions [18-21]. A study 
conducted by Aldieh revealed how a person living with 
HIV is affected by the co-infection with HPV. If left 
untreated, the HIV infection decreases the number of CD4 
positive lymphocytes. On the other hand, an HIV positive 
undetectable person has a pro-inflammatory status [22]. 
Another important exponent is smoking, which releases 
nicotine-derived ketones that lead to decreased local 
immunity [23]. 
The HPV infection is a sexually transmitted infection, 
and 75-80% of sexually active people have had the 
infection. Its natural evolution has several stages: latent 
infection (minimal clinical, colposcopic and 
histopathological changes) is the most common form of 
HPV infection. Active infection, without genomic 
integration (the virus replicates intensely, cell nuclei 
become large, multinucleated and hyperchromatic with a 
halo around the nucleus) corresponds to low-grade lesions 
(L-SIL) on the cytological evaluation. The evolution at this 
stage depends on the host's immune system. Antibodies 
directed against viral particles are produced by CD4 + T 
lymphocytes and macrophages. Most people produce these 
antibodies efficiently, so the evolution is favorable.    
The last stage in the evolution of the infection is the 
genomic integration, which corresponds to the malignant 
tumor pathology [24-28]. 
Clinical presentation 
Intraepithelial lesions do not have a characteristic 
symptomatology, most often we encounter abnormal 
vaginal bleeding, changes in bowel movement, changes in 
bladder function, pelvic pain syndrome, dyspareunia, 
macroscopic lesions on the exocervix [29-31]. 
Paraclinical evaluations 
The diagnosis of pre-invasive cervical lesions uses 
multiple paraclinical evaluations. 
Pap smear 
Pap smear examines cervical cellularity for abnormal 
cells. It is a screening method that must be done every three 
years. The appearance of a lesion on a properly performed 
screening is very small: 10-> 66 / 10,000. It is not 
recommended to be performed annually, as it does not 
decrease the risk of death from cervical cancer. A study 
conducted by Sawaya et al. covering patients aged 21 to 29 
years revealed that the risk of death from cervical cancer is 
identical, regardless of whether the cytological evaluation 
is done at one, two or three years [6,10,32]. 
The evaluation is not done during menstruation. It is 
important not to touch the exocervix when inserting the 
vaginal speculum, as dysplastic cells can attach to the 
speculum. Although during menstruation it is 
recommended not to perform the examination, it should not 
be delayed in case of cervicorrhagia, metrorrhagia or 
abnormal secretion because they can be symptoms of a 
malignant pathology of the cervix.  
On the referral note of the cytological examination, it 
is important to mention the date of the last menstruation, 
because the appearance of the vaginal and cervical 
epithelium varies with the ovarian cycle. Another thing to 
mention is pregnancy, exogenous hormone therapy, 
metrorrhagia, a history of dysplastic lesions, menopause, 
the use of intrauterine devices (IUD). In the case of IUD, 
it is recommended to take cells from the anterior vaginal 
wall as well, as these patients have an increased risk of 
developing vaginal cancer [33]. The Bethesda 2014 
classification is used to provide the cytological result. 
Intraerpithelial lesions are subdivided into several 
groups. Squamous cell atypia-like lesions (AUC): lesions 
of determined significance (AUC-US) or lesions that 
cannot rule out a high-grade lesion (AUC-H). Low-grade 
lesions L-SIL include CIN 1, HPV infection, mild 
dysplasia. High-grade lesions: H-SIL include severe, 
moderate dysplasia, CIN2, CIN3, carcinoma in situ and 
the invasive lesion represents squamous cell carcinoma of 
the cervix [34,35].   
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The HPV genotyping can be done alone or together 
with Pap smear once every 5 years. The most common 
strains 16, 18 are routinely tested on the cytological 
examination. It is useful to do it alone in patients who do 
not have access to screening services [11,34,36]. 
Colposcopy 
Colposcopy is used to evaluate the cervix. It is 
indicated in case of macroscopically visible genital tract 
lesions, abnormal cytological evaluation, positive HPV 
evaluation, intrauterine exposure to diethylstilbestrol, 
unexplained genital tract bleeding [12,33]. The 
examination can confirm if one has vulgar warts, cervicitis, 
pre-invasive lesions of the cervix, vagina or vulva.  
It has few risks; it allows the biopsy to be performed. 
Among the risks that arise after tissue sampling are: 
bleeding, infection and pelvic pain syndrome. Pre-
procedural training includes: no sexual intercourse 24-48 
hours before, no intravaginal tampons should be used 1-2 
days before, no intravaginal medication and no 
menstruation [37,38]. The examinations that are 
performed: the native macroscopic evaluation of the 
cervix, the examination with 3-5% acetic acid, which stains 
the aceto-white lesions, the Lahm-Schiller test using lugol. 
Normal cells have estrogen receptors; thus, those cells have 
glycerol in their cytoplasm. On the other hand, dysplastic 
cells lack these receptors and they have a lower quantity of 
glycerol. The last evaluation on colposcopy finds 
dysplastic cells using Lugol (an iodine solution).  If the 
cells have glycerol, iodine will impregnate them.  The last 
stage is omitted in the case of patients allergic to iodine or 
contrast agents. The results that suggest a cervical lesion 
are: acetone-white epithelium, mosaic, punctures and 
leukoplakia. 
The study conducted by Sophia S. analyzed the 
incidence of malignant tumor subtypes located in the 
cervix, and as a result of the screening programs, the 
incidence of squamous cell carcinoma of the cervix is 
decreasing, but the lack of experience in endocervical cell 
evaluation has led to an increase of endocervical 
adenocarcinomas [12,33]. 
Conization 
There are also invasive diagnostic methods: conization 
with the cold scalpel, conization with the electrocautery or 
excision with the diathermic loop.  
Conization with the cold scalpel offers a good piece for 
histopathological evaluation, it is simple, it requires 
general or local anesthesia, but it has a higher complication 
rate than other methods [39]. The patient is placed in a 
lithotomy position, the vaginal speculum is mounted, the 
colposcopic evaluation or Lugol can be used to observe the 
areas with lesions. Two sutures can be made at 3 and 9 
o'clock to limit bleeding. Sometimes it is useful to inject 
vasopressors which lead to a decrease in the intraoperative 
bleeding, in the absence of contraindications 
(hypertension). A circumferential incision is made that 
goes as deep as possible, it is excised and the neck is 
restored with Strumdorf suture [33]. 
Conization with the electrocautery offers a good 
specimen, good hemostasis and it has a lower complication 
rate, but it is more difficult, it can cause thermal damage in 
the adjacent structures, it is difficult to make a small radius 
cone [39-41]. 
The loop electrosurgical excision procedure is easy, 
fast, has few complications and provides a good piece for 
histopathological examination, but it can cause thermal 
damage to adjacent tissues and it is difficult to perform for 
a large area of tissue. Lidocaine can be used for local 
anesthetic purposes, but also to limit bleeding. It penetrates 
the cervix with a loop and in a single movement a fragment 
of the cervix is excised and sent for the histopathological 
examination [33,39,42]. 
A study conducted by Hu X looked at the rate of HPV 
infection among medical staff practicing electrocautery or 
diathermic excision. Procedures that lead to smoke 
generation are dangerous for doctors and nurses because 
they expose them to HPV that will be found to the nasal 
epithelium (the incidence is 9-10% among doctors who 
treat people positive for HPV, compared to 2- 3%). If 
medical personnel use KN95 masks, the infection was 0%. 
[43]. 
All these methods provide enough tissue for the 
pathological evaluation. The histopathological result is 
classified into CIN1, 2 and 3. CIN1 is also called L-SIL: 
mild, moderate dysplasia, located in the basal third, HPV 
infection, with an increased regression rate. High-grade 
intraepithelial lesions (H-SIL) are subdivided into CIN2 
and CIN3. CIN2: moderate dysplasia in two basal thirds, 
CIN3: severe dysplasia in two basal thirds, but can affect 
the entire epithelium, a situation called carcinoma in situ. 
[44]. 
A study led by Bansal, which included 680 patients, 
analyzed the evolution of CIN1 lesions. At 6 months after 
diagnosis: 49% regressed spontaneously, 35% had CIN1 
lesions, and 7% had a negative outcome. Out of the patients 
with negative lesions at 6 months, at the one-year 
reassessment: 80% had no lesions, 16% had low-grade 
intraepithelial lesions, and 4% had an unfavorable 
evolution. In the case of patients with positive lesions at 6 
months, at the one-year reassessment: 50% did not present 
lesions, 46% CIN1, and 4% evolved negatively [45,46]. 
The study conducted by Tainio K revealed that CIN2 
lesions in half of the cases regress without treatment. This 
meta-analysis covering 36 studies and including 3,160 
patients showed that at the two-year evaluation: 50% 
underwent regression of the lesion, 32% had persistent 
lesions, and 18% progressed to CIN3, carcinoma in situ, 
invasive cervical carcinoma [47]. 
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CIN3 lesions may regress spontaneously in 32-47% 
of cases or may progress to invasive carcinoma in 12-
40% of cases [48]. A study conducted by McCredie 
evaluated patients at 10 years and 30 years, comparing 
the patients' evolutions according to the treatment 
undergone. In the case of patients who opted for the 
expectant attitude, 20% developed invasive carcinoma 
at 10 years, and 31% developed malignant tumor 
pathology at 30 years. The patients who opted for the 
surgical treatment had an incidence of 0.3% at 10 years 
and 0.7% at 30 years [49]. 
HPV infection can be prevented by vaccination. It is 
recommended for all people between 11 and 26 years old 
and, in carefully selected cases, for people over 27 years 
old. It is recommended for women with a history of 
dysplasia and patients with vulgar warts. Vaccination has 
no therapeutic effects, but a decrease in the risk of 
recurrence has been observed. A meta-analysis performed 
by de Villiers EM et al. revealed that the recurrence in 
vaccinated patients is 1.9% compared to 5.9% in non-
vaccinated patients with CIN2 [50]. 
Conclusions 
Most pre-invasive cervical lesions are caused by the 
HPV infection, but not every infection causes the lesions, 
so it is not advisable to do it routinely among the young 
HPV genotypic population. 
The diagnosis of pre-invasive cervical lesions is 
eminently made through paraclinical investigations. 
Pap smear is an effective method of diagnosis and 
screening that must be performed every three years, 
performing it earlier does not reduce the risk of mortality 
from cervical cancer. 
If there is an abnormal Pap smear result, colposcopy is 
indicated for a thorough assessment of the squamous-
column transit area. Pathological lesions with pathological 
appearance are leukoplakia, mosaicism, punctures, aceto-
white epithelium. 
Invasive examinations provide the basis for the 
histopathological analysis, thus providing a careful 
assessment of the endocervix.  
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